Post by icemandios on Oct 26, 2020 12:51:16 GMT
Phio Pharmaceuticals Announces Three Poster Presentations at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting
MARLBOROUGH, Mass. , Oct. 26, 2020 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today announced three upcoming poster presentations discussing INTASYL compounds, including posters being delivered by two development partners, AgonOx, Inc. and the Helmholtz Zentrum München, at the 35th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2020), to be held virtually from November 9-14, 2020 .
Photo - mma.prnewswire.com/media/786567/Phio_Pharmaceuticals_Logo.jpg
Poster details are as follows:
Poster Sponsor:
Phio Pharmaceuticals
Title: Combination intratumoral treatment with INTASYL™ self-delivering RNAi
targeting TIGIT and PD-1/PD-L1 improves tumor control compared to
monotherapy in a CT26 model of murine colorectal cancer
Authors: Benjamin Cuiffo, et al.
Abstract Number: 198
Poster Sponsor: AgonOx, Inc.
Title: Increasing activation of human tumor-reactive T cells (CD39+CD103+CD8+) by
gene silencing of PD1 with self-delivering RNAi INTASYL TM
Authors: Colin J. Thalhofer, et al.
Abstract Number: 172
Poster Sponsor: Helmholtz Zentrum München
Title: New checkpoints controlling function of cytotoxic lymphocytes infiltrating human carcinoma
Authors: Anna Herbstritt, et al.
Abstract Number: 599
An archived version of the Phio presentation will be made available on the "Investors – Events and Presentations" section of the Company's website ( click here ).
About Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) is a biotechnology company developing the next generation of immuno-oncology therapeutics based on its self-delivering RNAi (INTASYL™) therapeutic platform. The Company's efforts are focused on silencing tumor-induced suppression of the immune system through its proprietary INTASYL platform with utility in immune cells and the tumor micro-environment. Our goal is to develop powerful INTASYL therapeutic compounds that can weaponize immune effector cells to overcome tumor immune escape, thereby providing patients a powerful new treatment option that goes beyond current treatment modalities. For additional information, visit the Company's website, www.phiopharma.com .
MARLBOROUGH, Mass. , Oct. 26, 2020 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL™) therapeutic platform, today announced three upcoming poster presentations discussing INTASYL compounds, including posters being delivered by two development partners, AgonOx, Inc. and the Helmholtz Zentrum München, at the 35th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2020), to be held virtually from November 9-14, 2020 .
Photo - mma.prnewswire.com/media/786567/Phio_Pharmaceuticals_Logo.jpg
Poster details are as follows:
Poster Sponsor:
Phio Pharmaceuticals
Title: Combination intratumoral treatment with INTASYL™ self-delivering RNAi
targeting TIGIT and PD-1/PD-L1 improves tumor control compared to
monotherapy in a CT26 model of murine colorectal cancer
Authors: Benjamin Cuiffo, et al.
Abstract Number: 198
Poster Sponsor: AgonOx, Inc.
Title: Increasing activation of human tumor-reactive T cells (CD39+CD103+CD8+) by
gene silencing of PD1 with self-delivering RNAi INTASYL TM
Authors: Colin J. Thalhofer, et al.
Abstract Number: 172
Poster Sponsor: Helmholtz Zentrum München
Title: New checkpoints controlling function of cytotoxic lymphocytes infiltrating human carcinoma
Authors: Anna Herbstritt, et al.
Abstract Number: 599
An archived version of the Phio presentation will be made available on the "Investors – Events and Presentations" section of the Company's website ( click here ).
About Phio Pharmaceuticals Corp.
Phio Pharmaceuticals Corp. (Nasdaq: PHIO) is a biotechnology company developing the next generation of immuno-oncology therapeutics based on its self-delivering RNAi (INTASYL™) therapeutic platform. The Company's efforts are focused on silencing tumor-induced suppression of the immune system through its proprietary INTASYL platform with utility in immune cells and the tumor micro-environment. Our goal is to develop powerful INTASYL therapeutic compounds that can weaponize immune effector cells to overcome tumor immune escape, thereby providing patients a powerful new treatment option that goes beyond current treatment modalities. For additional information, visit the Company's website, www.phiopharma.com .